Senti Biosciences (SNTI) Announces 1-for-10 Reverse Stock Split

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-ten (1-for-10) reverse stock split of Senti Bio’s common stock, par value $0.0001 per share (the “Common Stock”).

The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and Senti Bio’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on July 18, 2024. The CUSIP number of 81726A209 will be assigned to Senti Bio’s common stock when the reverse stock split becomes effective.

When the reverse stock split becomes effective, every ten (10) of Senti Bio’s issued shares of common stock will be combined into one issued share of common stock, without any change to the par value per share. This will reduce the number of outstanding shares of common stock from approximately 45.8 million shares to approximately 4.6 million shares.

No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fraction of a share of common stock of Senti Bio will receive a cash payment in lieu thereof at a price equal to that fraction of a share to which the stockholder would otherwise be entitled, multiplied by the closing price of Senti Bio’s common stock on Nasdaq on July 17, 2024 (as adjusted for the reverse split).

Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after July 18, 2024. Such beneficial holders may contact their bank, broker, or nominee for more information.

The reverse stock split ratio approved by the Board of Directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of Senti Bio at the 2024 Annual Meeting of Stockholders of Senti Bio.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Silexion Therapeutics faces Nasdaq delisting over equity shortfall
• Nuvectis Pharma (NVCT) files $200M mixed shelf